StockNews.AI
REGN
StockNews.AI
83 days

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

1. Regeneron partners with Telesis Bio for DNA synthesis technology. 2. The agreement enhances Regeneron’s R&D capabilities through automation.

2m saved
Insight
Article

FAQ

Why Bullish?

The partnership likely boosts REGN's efficiency in drug development, similar to past tech collaborations that enhanced operational capabilities, driving long-term value.

How important is it?

The collaboration with Telesis emphasizes innovation in drug development, which is critical for REGN’s growth.

Why Long Term?

Enhanced R&D capabilities can lead to significant discoveries, improving REGN's market position over time.

Related Companies

TBIOAMGNVRTX
SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at s.

Related News